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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
23.10.2020 Ventilation 
management 
and clinical 
outcomes in 
invasively 
ventilated 
patients with 
COVID-19 
(PRoVENT-
COVID): a 
national, 
multicentre, 
observational 
cohort study 
The Lancet 
Respiratory 
Medicine | 
Article 
• Little is known about the 
practice of ventilation 
management in patients 
with COVID-19 
• This national, 
multicentre, 
retrospective 
observational study at 
18 ICUs in the 
Netherlands, aimed to 
describe the practice of 
ventilation management 
and to establish 
outcomes in invasively 
ventilated patients with 
COVID-19 in a single 
country during the first 
month of the outbreak 
• Results add to existing 
knowledge about 
epidemiological 
characteristics and 
outcomes and could be 
useful in planning future 
studies and 
understanding previous 
findings about invasive 
ventilation in patients 
with COVID-19 
ventilation 
23.10.2020 Virology, 
transmission, 
and 
pathogenesis 
of SARS-
CoV-2 
BMJ | | 
Practice 
Clinical 
Update 
• A review providing a 
broad update on the 
emerging understanding 
of SARS-CoV-2 
pathophysiology, 
including virology, 
transmission dynamics 
and the immune 
response to the virus 
Virology, 
transmission, 
pathogenesis 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
22.10.2020 The temporal 
association of 
introducing 
and lifting non-
pharmaceutical 
interventions 
with the time-
varying 
reproduction 
number (R) of 
SARS-CoV-2: 
a modelling 
study across 
131 countries 
The Lancet 
Infectious 
Diseases | 
Article 
• This study quantifies 
the effects of both 
introducing and 
lifting NPIs with the 
level of transmission 
(R) of SARS-CoV-2 
in 131 countries 
• A global dataset of 
country-level daily R 
values was linked 
with a global dataset 
of country-level 
policies on NPIs to 
model the change in 
R values from day 1 
to 28 following the 
introduction and 
relaxation of 8 
individual NPIs 
among 131 countries 
• Individual NPIs 
including school 
closure, workplace 
closure, public 
events ban, ban on 
gatherings of more 
than ten people, 
requirements to stay 
at home, and internal 
movement limits, are 
associated with 
reduced 
transmission of 
SARS-CoV-2 
• The effect of 
introducing and 
lifting these NPIs is 
delayed by 1-3 
Non-
pharmaceutical 
interventions, 
transmission 
weeks, with this 
delay being longer 
when lifting NPIs 
• This additional 
evidence can inform 
policy-maker 
decisions on the 
timing of introducing 
and lifting different 
NPIs, interpreting R 
in the context of its 
known limitations, 
and when to expect 
a notable effect 
following the 
introduction or the 
relaxation 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
21.10.2020 Reusability of 
filtering 
facepiece 
respirators after 
decontamination 
through drying 
and germicidal 
UV irradiation 
BMJ Global 
Health | 
Original 
Research 
• Respirators can be 
recycled using drying 
and germicidal UV, a 
relatively simple and 
inexpensive 
procedure, in the case 
of shortages during a 
SARS pandemic with 
monitoring of the 
integrity and 
penetration efficiency 
of the respirators 
during disinfection-
recycling cycles 
Respirators, 
recycling 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
21.10.2020 Efficacy of 
Tocilizumab 
in patients 
hospitalized 
with Covid-
19 
NEJM | 
Original 
Article 
• Efficacy of IL-6 receptor 
blockade in hospitalised 
patients with Covid-19 who 
are not receiving 
mechanical ventilation is 
unclear 
• This randomised, double-
blind, placebo-controlled 
tocilizumab 
trial of 243 patients (58% 
men) with median age 
59.8y (21.7-85.4y) 
concludes that Tocilizumab 
(humanised monoclonal 
antibody that binds IL-6 
receptor) was not effective 
for preventing intubation or 
death in moderately ill 
hospitalised patients with 
Covid-19 
• Some benefit or harm 
cannot be ruled out though 
as confidence intervals for 
efficacy comparisons were 
wide 
20.10.2020 Effect of 
Tocilizumab 
vs standard 
care on 
clinical 
worsening in 
patients 
hospitalised 
with COVID-
19 
pneumonia: 
a 
randomized 
clinical trial 
JAMA Internal 
Medicine | 
Original 
Investigation 
• In this randomised clinical 
trial of 126 adult patients 
with COVID-19 pneumonia 
and Pa02/F102 ration 
between 200 and 300 mm 
Hg who received 
tocilizumab, no benefit on 
disease progression was 
observed compared with 
standard care 
• Further blinded, placebo-
controlled randomised 
clinical trials are needed to 
confirm the results and to 
evaluate possible 
applications of this drug in 
different stages of the 
disease 
tocilizumab 
20.10.2020 Effect of 
Tocilizumab 
vs usual care 
in adults 
hospitalized 
with COVID-
19 and 
moderate or 
severe 
pneumonia: 
a 
randomized 
clinical trial 
JAMA Internal 
Medicine | 
Original 
Investigation 
• In this randomised clinical 
trial of 130 patients 
hospitalised for Covid-19 
and moderate-to-severe 
pneumonia, tocilizumab 
may reduce the need for 
mechanical and non-
invasive ventilation or 
death by day 14 but not 
mortality by day 28 
• Further studies are 
necessary to confirm these 
preliminary results 
tocilizumab 
20.10.2020 Association 
between 
early 
JAMA Internal 
Medicine | 
• In this multicentre cohort 
study that included 3924 
patients, the risk of in-
hospital death was 
estimated to be lower with 
 tocilizumab 
treatment 
with 
tocilizumab 
and morality 
among 
critically ill 
patients with 
COVID-19 
Original 
Investigation 
tocilizumab treatment in 
the first 2 days of intensive 
care unit admission 
compared with no early 
use of tocilizumab 
• Findings though may be 
susceptible to unmeasured 
confounding, and authors 
call for further research 
from randomised clinical 
trials  
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
20.10.2020 A global 
survey of 
potential 
acceptance 
of a 
COVID-19 
vaccine 
Nature 
Medicine | Brief 
Communication 
• Authors conducted a 
survey of 13,426 people in 
19 countries to determine 
potential acceptance rates 
and factors influencing 
acceptance of a COVID-
19 vaccine 
• 71.5% (range 55-90%) 
participants reported that 
they would be very or 
somewhat likely to take a 
COVID-19 vaccine 
• 61.4% reported that they 
would accept their 
employer’s 
recommendation to take a 
COVID-19 vaccine 
• Those with higher levels 
of trust in information from 
government sources were 
more likely to accept a 
vaccine and take their 
employer’s advice to do 
so 
Vaccine 
acceptance  
 
  
Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
24.10.2020 Building a tuberculosis-free world while 
responding to the COVID-19 pandemic 
The Lancet | Comment 
23.10.2020 How Africa fought the pandemic – and what 
coronavirus has taught the world 
Financial Times | News 
23.10.2020 The engines of SARS-CoV-2 spread Science | Perspective 
23.10.2020 Roll out of rapid testing could be a ‘game 
changer’ for Africa 
Devex | News 
22.10.2020 Estimating the COVID-19 R number: a 
bargain with the devil? 
The Lancet Infectious Diseases 
21.10.2020 The challenges of expanding rapid tests to 
curb COVID-19 
JAMA Medical News & 
Perspectives 
21.10.2020 Understanding COVID-19 vaccine efficacy Science | Perspective 
20.10.2020 Time to reassess Tocilizumab’s role in Covid-
19 pneumonia 
JAMA Internal Medicine | 
Editorial 
20.10.2020 Lives vs. Livelihoods Revisited: Should 
poorer countries with younger populations 
have equally strict lockdowns? 
CGD | Blog 
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Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
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y 
C19 Resource Hubs   
Global  Regional 
& Country 
Academic 
journals & 
Publishers 
Institutes/Centres/
Funders/Other 
Health Topics Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of the 
WHO 
ICL MRC Centre 
for Global 
Infectious Disease 
Analysis 
Global 
Menstrual 
Collective  
Disability and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambridge 
University 
Press 
ODI SLH: 
Handwashing 
in low resource 
settings 
  Coregroup 
IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins 
University 
RBM 
Partnership 
  Ethics, health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochrane  Center for Global 
Development 
 Epidemic 
Preparedness 
Innovations 
  Social 
Development 
Direct C19 
blog series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID 
Repository 
    
UNOCHA OCHA 
Southern 
and 
Eastern 
Health Policy 
and Planning  
Norwegian 
Institute of Public 
Health 
    
Africa 
COVID-19 
Digest 
UNHCR  South 
African 
Governme
nt 
JAMA 
Network 
Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent 
Epidemics  
    
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
Online 
courses 
Varies WHO 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Available 
now 
Standard precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
Online 
learning 
3 hours WHO 
for detection, 
prevention, response 
and control 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2020. 
